SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

USFDA conducts GMP inspection of Sun Pharma’s Halol facility

14 Jun 2025 Evaluate

US Food and Drug Administration (USFDA) has conducted a Good Manufacturing Practices (GMP) inspection of Sun Pharmaceutical Industries’ Halol facility (Gujarat, India) from June 2, 2025 to June 13, 2025. At the conclusion of the inspection, the USFDA issued a Form-483, with 8 observations.

Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.


Sun Pharma. Inds. Share Price

1934.90 -3.95 (-0.20%)
10-Jul-2026 15:08 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1934.90
Dr. Reddys Labs. 1247.55
Cipla 1438.85
Zydus Lifesciences 1151.20
Lupin 2498.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: